TetraLogic prices relaunched IPO at $7

By Renaissance Capital,

Shutterstock photo

TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, raised $50 million by offering 7.2 million shares at $7. TetraLogic Pharmaceuticals plans to list on the NASDAQ under the symbol TLOG. TetraLogic Pharmaceuticals initially filed confidentially on 9/16/2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: TLOG

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com